Delcath Systems secures $25M committed equity financing facility Delcath Systems announced that it has obtained a committed equity financing facility under which it may sell up to $35M of its registered common stock to Terrapin Opportunity over a 24-month period. Delcath is not obligated to utilize any of the $35M facility and remains free to enter into and consummate other equity and debt financing transactions, subject to certain restrictions.
Delcath Systems begins enrollment for Phase trial of Melphalan/IDS Delcath Systems' intrahepatic cholangiocarcinoma study cohort of its expanded Global Phase 2 Clinical Trial Program of Melphalan/HDS for use in the treatment of patients with unresectable hepatocellular carcinoma - primary liver cancer, or HCC - has opened for patient enrollment. The ICC study will be conducted at the same hospitals in Europe participating in the company's Phase 2 HCC trial, and ICC enrollment is now open at Goethe University Hospital in Frankfurt, the Medical School Hannover and Jena University Hospital. Additional centers in Germany and the U.K. are expected to open for enrollment in the coming weeks.